Affimed (AFMD)
(Delayed Data from NSDQ)
$3.12 USD
+0.12 (4.00%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $3.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$3.12 USD
+0.12 (4.00%)
Updated Oct 14, 2024 04:00 PM ET
After-Market: $3.12 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Zacks News
Affimed N.V. (AFMD) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 11.11% and 9.57%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
by Zacks Equity Research
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affimed (AFMD) Starts AFM24-102 Study With Roche's Tecentriq
by Zacks Equity Research
Affimed (AFMD) starts recruiting patients in a phase I/IIa study to evaluate the combination of AFM24 and Roche's atezolizumab in solid tumors.
Affimed N.V. (AFMD) Reports Q3 Loss, Lags Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -30.77% and -13.34%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Affimed N.V. (AFMD) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
New Strong Sell Stocks for September 29th
by Zacks Equity Research
AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.
New Strong Sell Stocks for September 13th
by Zacks Equity Research
AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Will Affimed N.V. (AFMD) Report Negative Q2 Earnings? What You Should Know
by Zacks Equity Research
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affimed (AFMD) Enters Overbought Territory
by Zacks Equity Research
Affimed (AFMD) has moved higher as of late, but there could definitely be trouble on the horizon for this company
Company News for Apr 12, 2021
by Zacks Equity Research
Companies in the news are: AFMD, FUBO, GENE, CELC
Affimed (AFMD) Catches Eye: Stock Jumps 8.8%
by Zacks Equity Research
Affimed (AFMD) saw a big move last session, as its shares jumped nearly 9% on the day, amid huge volumes.
Affimed N.V. (AFMD) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 33.33% and 94.55%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -50.00% and -52.45%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
by Zacks Equity Research
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Affimed Continue to Surge Higher?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor of Affimed
Implied Volatility Surging for Affimed (AFMD) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Affimed (AFMD) stock based on the movements in the options market lately.
Affimed (AFMD) Catches Eye: Stock Jumps 7.2%
by Zacks Equity Research
Affimed (AFMD) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy
by Zacks Equity Research
Affimed N.V. (AFMD) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
New Strong Sell Stocks for November 27th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today
Affimed N.V. (AFMD) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of -35.71% and -65.47%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Affimed N.V. (AFMD) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
Affimed N.V. (AFMD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Affimed N.V. (AFMD) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Affimed N.V. (AFMD) delivered earnings and revenue surprises of 0.00% and -30.28%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
All You Need to Know About Affimed N.V. (AFMD) Rating Upgrade to Buy
by Zacks Equity Research
Affimed N.V. (AFMD) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Affimed (AFMD) Earnings and Sales Exceed Estimates in Q1
by Zacks Equity Research
Affimed (AFMD) exceeds earnings and sales estimates in the first quarter of 2019. The company also plans to focus its research and development investments.